Remimazolam (procedural sedation) – Benefit assessment according to §35a Social Code Book V

Report documents

1. Extract of dossier assessment

   Remimazolam (procedural sedation) – Benefit assessment according to §35a Social Code Book V

   published on

   01.04.2026

   Document type

   PDF document, 183 kB, DE, not accessible

   Download file : Extract of dossier assessment (PDF document, 183 kB, DE, not accessible)
2. Dossier assessment

   Remimazolam (procedural sedation) – Benefit assessment according to §35a Social Code Book V

   published on

   01.04.2026

   Document type

   PDF document, 862 kB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/A25-161

   Download file : Dossier assessment (PDF document, 862 kB, DE, not accessible)

Drug assessment at a glance

1. Drug assessment at a glance

   Remimazolam (procedural sedation) – Benefit assessment according to §35a Social Code Book V

   published on

   29.10.2026

   Document type

   PDF document, 202 kB, EN, not accessible

   Download file : Drug assessment at a glance (PDF document, 202 kB, EN, not accessible)

Dossier assessment

Project details

Project no.

A25-161

Commission

Commission awarded on 23.12.2025 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Surgery

Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-161

Connected Projects

1. Dossier assessment

   Remimazolam (general anaesthesia) – Benefit assessment according to §35a Social Code Book V

   Project no.

   A25-162

   Last updated

   01.04.2026

   Status: Commission completed